GlassScriptPhysician profile
Beth M Delambo
NPI 1568775153
$6,960.02
in general payments reported to CMS, 2019-2025
24 companies · $1,827 in 2025
The $1,827 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $479 · 2022: $1,774 · 2023: $1,510 · 2024: $1,369 · 2025: $1,827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,691 · Education: $15.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,690.75 |
| Education | $15.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,006.14 | 2021-2025 | Caplyta |
| Alkermes, INC. | $703.43 | 2021-2025 | Aristada, Lybalvi |
| Abbvie INC. | $624.80 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $584.56 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $538.19 | 2022-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $497.91 | 2021-2025 | Spravato |
| Supernus Pharmaceuticals, INC. | $388.96 | 2023-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $316.26 | 2022-2024 | Jornay Pm |
| Tris Pharma INC | $282.13 | 2022-2024 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $275.83 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $260.89 | 2022-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $239.51 | 2021-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $234.66 | 2021-2023 | Ingrezza |
| Lundbeck LLC | $218.07 | 2021-2024 | Rexulti |
| Bausch Health US, LLC | $199.49 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $135.86 | 2021-2025 | Xelstrym, Secuado |
| Vanda Pharmaceuticals INC. | $118.92 | 2022-2025 | Fanapt |
| Neos Therapeutics, LP | $88.33 | 2022-2023 | Adzenys Xr-Odt |
| Teva Pharmaceuticals USA, INC. | $76.46 | 2022-2024 | Austedo Xr, Uzedy |
| Idorsia Pharmaceuticals US INC | $59.71 | 2023 | Quviviq |
| Almatica Pharma LLC | $34.67 | 2025 | Loreev Xr |
| Merck Sharp & Dohme LLC | $34.29 | 2022 | |
| Biogen, INC. | $22.93 | 2025 | Zurzuvae |
| Indivior INC. | $18.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Delambo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.